BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioResources

Innovations in Hematologic Oncology: Addressing Unmet Needs in CLL Care

Lymphocyte Type, Blood Cancer Chronic lymphocytic leukaemia (CLL) is a blood malignancy caused by an overproduction of lymphocytes in the blood, lymphatic...

July 13, 2026 | Analysis

Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?

Scope 3 clauses, single-use plastic, water and energy intensity: the “green premium” has become the defining question for the CDMOs that built ...

July 13, 2026 | Analysis

The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.

A control room that thinks it knows what happens next Walk the mezzanine above a modern biologics suite in Singapore, Songdo or Hyderabad and the change i...

July 13, 2026 | Analysis

Can APAC Build Radioligand Therapy Before the Atoms Decay?

Every dose of radioligand therapy is a countdown. The moment a batch of lutetium-177 leaves the reactor, it begins to fade — roughly half its therape...

July 02, 2026 | Analysis

Icosagen Completes €45 Million Expansion to Deliver End-to-End Biologics Development and GMP Manufacturing at a Single Site

Estonia-based biotechnology company Icosagen has completed a major strategic expansion to strengthen its integrated biologics development and man...

July 01, 2026 | News

The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026

For three years the biotechnology industry waited for a turn. The first half of 2026 delivered one — and then several more in quick succession. In si...

June 30, 2026 | Analysis

Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?

A new medicine arrives at a regulator's desk with two kinds of proof attached. The first is the familiar kind: a randomised controlled trial, blinded, cont...

June 30, 2026 | Analysis

Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next

For most of the last decade, the strategic case for running Asia-Pacific clinical trials could be summarised in a single word: China. A vast, treatment-n...

June 29, 2026 | Analysis

Vendor to Co-Innovator — or Bring It In-House? The CDMO Relationship Rewires

For two decades the contract development and manufacturing organisation occupied a comfortable, clearly understood place in the biopharma value chain. The ...

June 25, 2026 | Analysis

Plastic, Steel and Software: APAC’s Next-Generation Bioprocessing Choice

When a biologics manufacturer in Bengaluru, Songdo or Singapore signs off on a new production suite today, the hardest question is rarely which molecule to...

June 23, 2026 | Analysis

After the Drug Substance, the Real Squeeze: APAC's Aseptic Fill-Finish Gap

For most of the last decade, the anxiety in Asia-Pacific biomanufacturing pointed upstream. The conversation was about bioreactor volume — how many t...

June 22, 2026 | Analysis

Billions on Bioconjugation: Is APAC Building the Right ADC Capacity — or Too Much?

In Songdo, on the reclaimed waterfront west of Seoul, a 202,000-square-metre construction site is becoming the most expensive single statement Kore...

June 19, 2026 | Analysis

World-Class Plants, Who Will Run Them? APAC's Biomanufacturing Skills Gap

Walk into one of the gleaming new large-molecule plants going up across Songdo, Tuas or Hyderabad and the first impression is of inevitability. The...

June 18, 2026 | Analysis

Agility or Corner-Cutting? Asia's Accelerated-Approval Gamble

On 1 April 2026, Japan's Pharmaceuticals and Medical Devices Agency did something no other major medicines regulator had done before it: from that date, ev...

June 17, 2026 | Analysis

Stay Connected